What is postherpetic neuralgia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Postherpetic Neuralgia?

Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that persists for 3 months or more following the healing of a herpes zoster (shingles) rash, resulting from reactivation of the dormant varicella zoster virus in dorsal root ganglia. 1, 2, 3

Pathophysiology and Mechanism

PHN represents a distinct disease entity separate from acute herpes zoster, involving aberrant somatosensory processing in both peripheral and central nervous systems. 4 The condition is characterized by:

  • Inflammatory necrosis of dorsal root ganglia with associated neuritis, leptomeningitis, and segmental unilateral degeneration of related motor and sensory roots 5
  • Peripheral nerve fiber damage with secondary central brain changes, resulting in altered sensory and nerve function including upregulation of nociception at every level of the nervous system 1
  • Denervation pain where deprivation of coherent sensory information produces pain that conveys incorrect messages, rather than pain from overstimulation 1

Clinical Presentation

Patients with PHN typically experience multiple distinct pain types:

  • Continuous burning, tingling, itchy, or tender sensations that persist in the dermatomal distribution where the original shingles rash occurred 1
  • Paroxysmal lancinating pain that can be sharp and shooting in character 5, 3
  • Allodynia where typically non-painful stimuli (such as light touch or clothing contact) trigger severe pain 3
  • Hyperalgesia where painful stimuli produce exaggerated pain responses beyond what would be expected 3

Epidemiology and Risk Factors

The most significant risk factor for developing PHN is advanced age, with at least 50% of shingles patients over age 65 developing PHN. 2, 5 Additional risk factors include:

  • Severity of pain during acute shingles correlates with higher PHN risk 2
  • Trigeminal nerve distribution of the original herpes zoster infection 2
  • Immunocompromised states, particularly advanced HIV disease where PHN can be incapacitating 1, 6
  • Psychological distress and stressful life events appear to play a role in both shingles onset and PHN development 7

Natural History and Prognosis

  • PHN accounts for 11-15% of all pain clinic referrals, representing a significant burden on healthcare systems 2
  • Pain may persist for months to years in affected patients, with some requiring long-term treatment 8, 7
  • The condition often leads to depression, disrupted sleep, decreased functioning, and increased healthcare utilization due to its chronic and refractory nature 7
  • The rash itself evolves through stages of vesicles, pustules, and crusts, with new vesicle formation continuing for 3-5 days and crusts typically persisting for 2-3 weeks before resolving 6

Common Pitfalls

A critical caveat is that PHN is frequently unresponsive to treatment modalities, with response to therapy being generally inhomogeneous across patients. 4 Some patients achieve long-term pain control with monotherapy, while others—particularly those with central nervous system lesions—remain extraordinarily refractory to all measures. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The management of postherpetic neuralgia.

Postgraduate medical journal, 1997

Research

Post-herpetic Neuralgia: a Review.

Current pain and headache reports, 2016

Research

Treatment options in postherpetic neuralgia.

Acta neurologica Scandinavica. Supplementum, 1999

Research

Postherpetic neuralgia: the never-ending challenge.

Pain practice : the official journal of World Institute of Pain, 2005

Guideline

Duration of Shingles Pain

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Post-herpetic neuralgia case study: optimizing pain control.

European journal of neurology, 2004

Guideline

Treatment Options for Post-Herpetic Neuralgia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.